MRI Interventions ClearPoint(R) Neuro Navigation System Recognized as Realtime Solution for Frameless Brain Biopsy in the Journal of Neurosurgery
IRVINE, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced the publication of a Technical Note in the Journal of Neurosurgery regarding the use of the Company's ClearPoint Neuro Navigation System in frameless, MRI-guided brain biopsy. The Technical Note highlighted the ClearPoint System's safety advantages of real-time visualization, ability to make adjustments and confirmation of trajectory and targeting through a minimally invasive approach.
Traditional frame-based stereotactic biopsies rely on preoperative images which limit the ability to account for the shift of intracranial structures, which may reduce the target accuracy at the biopsy site resulting in a missed sample.
"The ClearPoint system has already been used with Electrode Placement, Drug Infusion and Laser Ablation," said Dr. J. Bradley Elder, Associate Professor of Neurological Surgery at The Ohio State University Wexner Medical Center. "Application of this technology to biopsy provides real time adaptability for needle trajectory, immediate imaging of complications and could eliminate misdiagnosis," said Dr. Elder.
The ClearPoint Neuro Navigation System is the only technology that enables minimally-invasive neurosurgery under continuous MRI guidance, offering surgeons real-time direction and a direct view of the inside of a patient's brain during a procedure. MRI provides superior visualization of the brain's tissue compared to other imaging technologies.
About MRI Interventions, Inc.
Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. The ClearPoint system, which has received 510(k) clearance and is CE marked, utilizes a hospital's existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: customer demand and market acceptance of our products; our ability to successfully expand, and achieve full productivity from, our sales, clinical support and marketing capabilities; our ability to achieve the full benefits from cost reduction efforts that have been implemented or are pending; the sufficiency of our cash resources to maintain planned commercialization efforts; and future actions of the U.S. Food and Drug Administration or any other regulatory body that could impact our commercialization efforts. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2014, as well as the Company's Form 10-Q for the quarter ended March 31, 2015, which have been filed with the Securities and Exchange Commission.
CONTACT: MRI Interventions, Inc. Wendelin Maners, Vice President Marketing 949-900-6833